Semaglutide and Cagrilintide: Interaction Evidence
App Library Tools Pricing Download
[Interaction checker]

Semaglutide and Cagrilintide

Caution · Human study · Reviewed

Short answer: Tested together as CagriSema, an investigational fixed combination; most users had stomach side effects.

  • FlagCaution
  • EvidenceHuman study
  • Sources2
  • Last reviewedOctober 22, 2026

What is known

Cagrilintide plus semaglutide (CagriSema) has been tested in large trials as a single investigational product, not as a do-it-yourself stack. In the phase 3 REDEFINE 1 trial, average weight loss was 20.4% at 68 weeks vs 3.0% on placebo. Gastrointestinal side effects affected 79.6% vs 39.9% on placebo, mostly mild to moderate and temporary.

The phase 2 trial in 92 people with type 2 diabetes found 15.6% weight loss at 32 weeks with CagriSema vs 5.1% with semaglutide and 8.1% with cagrilintide alone. Trial products were made and dosed under study conditions; results don't apply to separately sourced cagrilintide. No FDA label for cagrilintide was found on DailyMed as of October 2026.

How strong the evidence is

Human study. At least one published study in people speaks to this pair. Caution: There is a documented or likely risk to watch for, such as low blood sugar or added side effects. Talk to your prescriber before combining.

Guides: Semaglutide, Cagrilintide. To check this pair alongside others, open it in the peptide interaction checker.

Education only, not medical advice. "No known interaction" means we found nothing reported, not that a combination is safe. Most of the peptides here are not FDA approved, and most pairs have never been studied together in people. Talk to your clinician or pharmacist before you start, stop or combine anything.

Sources

  1. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 2025. PMID 40544433
    Phase 3a REDEFINE 1 (n=3417): -20.4% body weight at 68 weeks vs -3.0% placebo; GI adverse events 79.6% vs 39.9%.
  2. Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet, 2023. PMID 37364590
    Phase 2 in type 2 diabetes (n=92): weight change -15.6% CagriSema vs -5.1% semaglutide vs -8.1% cagrilintide at 32 weeks.

Other reviewed pairs with Semaglutide